ChAd63 ME-TRAP

BIOLOGICAL4 trials

Sponsors

University of Oxford, University Hospital Tuebingen, THE JENNER INSTITUTE, UNIVERSITY OF OXFORD

Conditions

MalariaPlasmodium Falciparum Malaria

Phase 1

A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S

CompletedNCT01883609

University of OxfordPlasmodium Falciparum Malaria

Start: 2013-09-30End: 2014-08-31Updated: 2014-10-01

A Safety and Efficacy Study of R21 +/- ChAd63/MVA ME-TRAP

CompletedNCT02905019

University of OxfordMalaria

Start: 2016-08-31End: 2017-12-21Updated: 2018-06-13

Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults

Not yet recruitingNCT05441410

University Hospital TuebingenMalaria

Start: 2025-06-01End: 2026-06-30Target: 30Updated: 2024-12-06

Unknown Phase

Malaria vectored vaccines and EPI co-administration trial (VAC 058)

Active, not recruitingPACTR201402000749217

THE JENNER INSTITUTE, UNIVERSITY OF OXFORDMalaria

Start: 2014-03-03Target: 65Updated: 2026-01-27

Related Papers

R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.

2025-01-106 citations

Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial

Frontiers in Immunology2017-11-2027 citations

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01<sub>B</sub>With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP

The Journal of Infectious Diseases2016-06-1594 citations